A Phase I Open-Label, 2-Part, 3-Cohort, Single-Centre Study to Assess the Concentration of Avibactam and Ceftazidime in Epithelial Lining Fluid and Plasma Using at Least Two Different Dosing Regimens in Healthy Volunteers.

Trial Profile

A Phase I Open-Label, 2-Part, 3-Cohort, Single-Centre Study to Assess the Concentration of Avibactam and Ceftazidime in Epithelial Lining Fluid and Plasma Using at Least Two Different Dosing Regimens in Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Sep 2017

At a glance

  • Drugs Avibactam/ceftazidime (Primary)
  • Indications Gram-negative infections; Intra-abdominal infections; Nosocomial infections; Urinary tract infections
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 25 Apr 2017 Results assessing population pharmacokinetic modelling of ceftazidime and avibactam in healthy volunteers presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases.
    • 13 Sep 2013 Results presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy.
    • 14 Aug 2012 Actual end date (1 Jul 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top